|Bid||84.26 x 1000|
|Ask||84.28 x 800|
|Day's Range||84.08 - 85.03|
|52 Week Range||66.10 - 87.35|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||23.66|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||2.20 (2.61%)|
|1y Target Est||95.93|
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
The Zacks Analyst Blog Highlights: Procter & Gamble, United Technologies, Boeing, Merck & Co. and Apple
The Bedford startup is hoping to become the leader in an emerging method of fighting cancer — and it’s launching with a commercial partnership already in place.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.
Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L
Merck (MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live). If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO® (pronounced UR-VEE-BOH) and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The CHMP’s recommendation, completed under accelerated assessment, will now be considered by the European Commission.
Merck & Co. Inc. is eliminating 500 jobs in multiple states including Pennsylvania. The job cuts are effective Jan. 3., 2020, and include remote workers residing outside of the state, according to a filing with the Pennsylvania Department of Labor and Industry. Pamela Eisele, a spokeswoman for the pharmaceutical giant, said the filing relates to "several changes" in the company's U.S. commercial organization tied to its research and development focus going forward.
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 8,120,633 common shares at a price of C$0.07 per common share for gross proceeds of C$568,444.
Johnson and Johnson (NYSE:JNJ) stock was recently upgraded to Outperform by a Bernstein analyst as "historically cheap." JNJ stock is off its 52-week highs almost 12%. It seems the market has basically discounted in its present legal issues and potential liabilities.Source: Sundry Photography / Shutterstock.com Investors should consider the company's underlying strengths both as a pharmaceutical company and a consumer. The pharma segment accounts for half of its revenues and profits. JNJ Stock Benefits From Powerful Free Cash FlowIn JNJ's latest 10-Q report, it reported almost $9.5 billion in operating cash flow for the six months to June 30. After deducting $1.49 billion in capital expenditures, JNJ's free cash flow (FCF) was $8 billion. That works out to $16 billion annually.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Beverage Stocks to Buy Now Johnson and Johnson's dividends cost only $4.9 billion in the first half, or $9.8 billion annually. That is just 61% of its annual $16 billion FCF. In fact, JNJ spent $4.7 billion on share buybacks or 59% of its FCF.That means JNJ's return of capital payments to shareholders are greater than its FCF. These represent $9.6 billion in total payments in the first half. Annualized that works out to $19.2 billion, or 5.5% of the Johnson and Johnson stock market value. JNJ Can Afford the Legal Fines and Excess Return of CapitalJohnson and Johnson can afford to both pay out more than its FCF to shareholders in dividends and share buybacks as well as any litigation settlements. It has at least four ways to do this.For example, it can sell or dispose of assets to raise cash, draw down its cash and securities balances, increase debt, or use share issuances (from employee options). Often JNJ will use a mixture of all of these, especially if it also decides to purchase smaller companies at the same time.In case it has to pay out legal settlements or penalties, JNJ may have insurance and certain reserves to protect itself. Analysts assume that the company will use a mixture of all these methods to also pay the legal liabilities that may eventually arise.Bernstein's analyst report indicates that JNJ's maximum settlement exposure is no more than $50 billion. Even if it had to pay this amount all at once, which is highly unlikely, Johnson and Johnson could afford to take on debt to pay this amount.For example, JNJ has $155 billion in assets, including $15 billion in cash and securities, and only $27 billion in long-term debt. This leaves ample room, including with its free cash flow, to pay a worst-case scenario of $50 billion. JNJ Stock Is Undervalued Compared to PeersJNJ's market value of $346 billion. It has a FCF yield of 4.6% ($16 billion divided by its $346 billion market value) and a total yield of 5.5% (dividends and buybacks divided by the market value).JNJ's FCF yield is higher than peers its size. For example, Pfizer (NYSE:PFE) produced operating cash flow of $4.3 billion in the six months to June 30. Since capex was $939 million its FCF was $3.37 billion or annualized $6.7 billion. Since PFE stock's market value is $200 billion, its FCF yield is just 3.37%.The same is true with Merck (NYSE:MRK). MRK produced $3.04 billion in FCF in the first half of 2019 and its market value is $216 billion. So that gives it a FCF yield of just 2.8%.JNJ's stock market value is larger than both PFE and MRK. Its FCF yield is also higher. This means the Johnson and Johnson stock price is very undervalued compared to its large peers. JNJ Has Credibility From Its Tylenol Decision Decades AgoJNJ still holds a lot of "street credibility." This is due to JNJ's 1983 decision to recall all Tylenol bottles when one was criminally tampered with. In the March-April 1994 issue of Harvard Business Review, Lynne Payne, a Harvard Business school professor, wrote about Johnson and Johnson's famous Tylenol recall decision, in her article,"Managing for Organizational Integrity." She points out that integrity was not just with the CEO's integrity, but all JNJ's employees:"For example, Johnson & Johnson's handling of the Tylenol crisis is sometimes attributed to the singular personality of then-CEO James Burke. However, the decision to do a nationwide recall of Tylenol capsules in order to avoid further loss of life from product tampering was in reality not one decision but thousands of decisions made by individuals at all levels of the organization. The "Tylenol decision," then, is best understood not as an isolated incident, the achievement of a lone individual, but as the reflection of an organization's culture. Without a shared set of values and guiding principles deeply ingrained throughout the organization, it is doubtful that Johnson & Johnson's response would have been as rapid, cohesive, and ethically sound."I believe that Johnson and Johnson company still benefits from this aura of integrity, at least on Wall Street. JNJ stock has not completely fallen out of bed despite its huge legal challenges. In other words, it's not just the financial strength of the company that upholds Johnson and Johnson stock. It's also JNJ's reputation for integrity. Stay Tuned for JNJ Stock Reaching Intrinsic ValueJohnson and Johnson will announce its third-quarter results on Oct. 15. Watch to see what JNJ believes its ultimate settlement exposure may be. Also, look at whether it is continuing to spend more on dividends and share repurchases than its free cash flow.That will be a good sign showing what management believes about the Johnson and Johnson stock price. A dividend increase and further buybacks will show that JNJ's stock price is still selling well below its intrinsic value.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks, which includes both dividend and buyback yields. In addition, subscribers a two-week free trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Beverage Stocks to Buy Now * 10 Groundbreaking Technologies Created by Universities * 5 Semiconductor Stocks Worth Your Time The post Johnson and Johnson Stock Still Significantly Undervalued appeared first on InvestorPlace.
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jennifer Peterson, a tax partner at KPMG LLP, went through years of treatments, doctor's appointments and insurance calls before honing in on a successful therapy.
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, explains in a new interview why he decided to publicly resign from one of President Trump’s councils in the summer of 2017.
“Every person running for president has a plan to reduce pharmaceutical pricing,” Merck CEO Kenneth Frazier says. “Some of them I think are legitimate plans, some of them will hurt innovation, which we don’t want.”
Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
In a conversation with Yahoo Finance, Merck CEO Kenneth Frazier discusses an array of topics from drug price affordability to the anti-vaccination movement to his decision to step down from President Trump's American Manufacturing Council.
The Yahoo Finance All Markets Summit: Generational Opportunities event brings together leaders in business, government and a host of influencers who are shaping and defining new relationships in a time of profound generational change.